Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of VG161 in advanced bone and soft tissue sarcoma after first-line treatment failure
CTR20231564Phase 2Active
- Sponsor
- Sinopharm CNBG-Virogin Biotech
- Start
- Aug 2023
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of VG161 in bone cancer, soft tissue sarcoma (STS), sponsored by Sinopharm CNBG-Virogin Biotech. Started Aug 2023; status: active.
02
Drugs
VG161
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20231564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231564.